person · Reporting owner

Hunkapiller Michael

Disclosed activity across 2 companies

Tapewire entity: 142005
SEC CIK: 0001317102

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650	Director	February 26, 2021	March 03, 2021
Venus Concept Inc.HAIR · Entity 55304	10% owner	October 16, 2017	October 17, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Report date February 26, 2021 · Filed March 03, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	848,405	Ending reported balance After 2021-02-26 transaction · row 7 7 source rows · reconciled sequence Row 1 · 2021-02-26 · Exercise / conversion · Acquired 109,749 · Balance 958,154 Row 2 · 2021-02-26 · Exercise / conversion · Acquired 79,363 · Balance 1,037,517 Row 3 · 2021-02-26 · Exercise / conversion · Acquired 45,134 · Balance 1,082,651 Row 4 · 2021-02-26 · Sale · Disposed 170,824 · Balance 911,827 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F2: This sale price represents the weighted average sale price of the shares sold ranging from $30.20 to $31.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Row 5 · 2021-02-26 · Sale · Disposed 43,946 · Balance 867,881 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F3: This sale price represents the weighted average sale price of the shares sold ranging from $31.20 to $32.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Row 6 · 2021-02-26 · Sale · Disposed 15,771 · Balance 852,110 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F4: This sale price represents the weighted average sale price of the shares sold ranging from $32.23 to $33.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Row 7 · 2021-02-26 · Sale · Disposed 3,705 · Balance 848,405 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F5: This sale price represents the weighted average sale price of the shares sold ranging from $33.23 to $33.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.72 · Expires 2025-03-16	Direct	0	Reported balance After 2021-02-26 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-02-26 · Exercise / conversion · Disposed 109,749 · Balance 0 F6: The shares subject to the option are fully vested and exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.87 · Expires 2026-03-15	Direct	0	Reported balance After 2021-02-26 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-02-26 · Exercise / conversion · Disposed 79,363 · Balance 0 F6: The shares subject to the option are fully vested and exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.27 · Expires 2027-02-15	Direct	0	Reported balance After 2021-02-26 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2021-02-26 · Exercise / conversion · Disposed 45,134 · Balance 0 F6: The shares subject to the option are fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020.

F2: This sale price represents the weighted average sale price of the shares sold ranging from $30.20 to $31.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F3: This sale price represents the weighted average sale price of the shares sold ranging from $31.20 to $32.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F4: This sale price represents the weighted average sale price of the shares sold ranging from $32.23 to $33.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F5: This sale price represents the weighted average sale price of the shares sold ranging from $33.23 to $33.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F6: The shares subject to the option are fully vested and exercisable.

Venus Concept Inc.

Report date October 16, 2017 · Filed October 17, 2017

Jointly reported with ALLOY VENTURES 2002 LLC, KELLY DOUGLAS E, Shoch John, Di Bona Tony, Rubin Daniel, Hanafi Ammar

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	12,466	Reported balance After 2017-10-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-10-16 · Conversion · Acquired 12,466 · Balance 12,466 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	26,116	Reported balance After 2017-10-16 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2017-10-16 · Conversion · Acquired 13,650 · Balance 26,116 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	42,759	Reported balance After 2017-10-16 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2017-10-16 · Conversion · Acquired 16,643 · Balance 42,759 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	45,041	Reported balance After 2017-10-16 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2017-10-16 · Conversion · Acquired 2,282 · Balance 45,041 F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	461,717	Reported balance After 2017-10-16 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2017-10-16 · Conversion · Acquired 461,717 · Balance 461,717 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	967,297	Reported balance After 2017-10-16 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2017-10-16 · Conversion · Acquired 505,580 · Balance 967,297 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,583,743	Reported balance After 2017-10-16 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2017-10-16 · Conversion · Acquired 616,446 · Balance 1,583,743 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,668,269	Reported balance After 2017-10-16 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2017-10-16 · Conversion · Acquired 84,526 · Balance 1,668,269 F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	474,184	Reported balance After 2017-10-16 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2017-10-16 · Conversion · Acquired 474,184 · Balance 474,184 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	993,414	Reported balance After 2017-10-16 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 10 · 2017-10-16 · Conversion · Acquired 519,230 · Balance 993,414 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,626,508	Reported balance After 2017-10-16 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 11 · 2017-10-16 · Conversion · Acquired 633,094 · Balance 1,626,508 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,713,317	Reported balance After 2017-10-16 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 12 · 2017-10-16 · Conversion · Acquired 86,809 · Balance 1,713,317 F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-16 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2017-10-16 · Conversion · Disposed 12,466 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-16 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2017-10-16 · Conversion · Disposed 461,717 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-16 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2017-10-16 · Conversion · Disposed 474,184 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-16 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2017-10-16 · Conversion · Disposed 13,650 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-16 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2017-10-16 · Conversion · Disposed 505,580 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-16 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2017-10-16 · Conversion · Disposed 519,230 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-16 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2017-10-16 · Conversion · Disposed 16,643 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-16 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2017-10-16 · Conversion · Disposed 616,446 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-16 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2017-10-16 · Conversion · Disposed 633,094 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $7.00	IndirectSee Footnote	0	Reported balance After 2017-10-16 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2017-10-16 · Conversion · Disposed Not disclosed · Balance 0 F6: The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the "Note"). The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO. F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $7.00	IndirectSee Footnote	0	Reported balance After 2017-10-16 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2017-10-16 · Conversion · Disposed Not disclosed · Balance 0 F6: The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the "Note"). The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO. F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $7.00	IndirectSee Footnote	0	Reported balance After 2017-10-16 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2017-10-16 · Conversion · Disposed Not disclosed · Balance 0 F6: The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the "Note"). The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO. F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO").

F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

F5: The expiration date is not relevant to the conversion of these securities.

F6: The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the "Note"). The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 26, 2021 Filed Mar 3, 2021 01:31 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	45,134	$0.00 Strike: $5.27	$0.00	Disclosure SEC source: 0001299130-21-000107 · certent-form4.xml · derivative · entry 10 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,134 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:31 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	79,363	$0.00 Strike: $7.87	$0.00	Disclosure SEC source: 0001299130-21-000107 · certent-form4.xml · derivative · entry 9 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 79,363 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:31 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	109,749	$0.00 Strike: $5.72	$0.00	Disclosure SEC source: 0001299130-21-000107 · certent-form4.xml · derivative · entry 8 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,749 shares Expires 2025-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:31 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	3,705	$33.33	$123,487.65	Disclosure SEC source: 0001299130-21-000107 · certent-form4.xml · nonDerivative · entry 7 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F5 · price: This sale price represents the weighted average sale price of the shares sold ranging from $33.23 to $33.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:31 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	15,771	$32.74	$516,311.00	Disclosure SEC source: 0001299130-21-000107 · certent-form4.xml · nonDerivative · entry 6 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,110 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F4 · price: This sale price represents the weighted average sale price of the shares sold ranging from $32.23 to $33.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:31 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	43,946	$31.49	$1,383,991.38	Disclosure SEC source: 0001299130-21-000107 · certent-form4.xml · nonDerivative · entry 5 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,881 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $31.20 to $32.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:31 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	170,824	$30.69	$5,242,076.09	Disclosure SEC source: 0001299130-21-000107 · certent-form4.xml · nonDerivative · entry 4 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 911,827 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $30.20 to $31.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:31 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	45,134	$5.27	$237,856.18	Disclosure SEC source: 0001299130-21-000107 · certent-form4.xml · nonDerivative · entry 3 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:31 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	79,363	$7.87	$624,586.81	Disclosure SEC source: 0001299130-21-000107 · certent-form4.xml · nonDerivative · entry 2 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:31 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	109,749	$5.72	$627,764.28	Disclosure SEC source: 0001299130-21-000107 · certent-form4.xml · nonDerivative · entry 1 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 958,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 25, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	135,759	$0.00 Strike: $5.27	$0.00	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · derivative · entry 24 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,134 Underlying: Common Stock · 135,759 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 25, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	135,882	$0.00 Strike: $7.87	$0.00	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · derivative · entry 23 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,363 Underlying: Common Stock · 135,882 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 25, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	67,736	$0.00 Strike: $5.72	$0.00	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · derivative · entry 22 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,749 Underlying: Common Stock · 67,736 shares Expires 2025-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 25, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	3,238	$35.68	$115,531.84	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 17 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. Read SEC document
February 25, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	29,500	$34.73	$1,024,476.00	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 16 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,643 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F10 · price: This sale price represents the weighted average sale price of the shares sold ranging from $34.53 to $35.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 25, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	49,410	$34.21	$1,690,266.69	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 15 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,143 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F9 · price: This sale price represents the weighted average sale price of the shares sold ranging from $33.53 to $34.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 25, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	23,331	$32.88	$767,053.29	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 14 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930,553 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F8 · price: This sale price represents the weighted average sale price of the shares sold ranging from $32.52 to $33.51 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 25, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	123,383	$31.97	$3,944,677.89	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 13 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,884 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F7 · price: This sale price represents the weighted average sale price of the shares sold ranging from $31.52 to $32.51 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 25, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	110,515	$31.05	$3,430,938.18	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 12 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,267 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F6 · price: This sale price represents the weighted average sale price of the shares sold ranging from $30.52 to $31.51 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 25, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	135,759	$5.27	$715,449.93	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 11 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,187,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 25, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	135,882	$7.87	$1,069,391.34	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 10 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 25, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	67,736	$5.72	$387,449.92	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 9 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 916,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	87,374	$0.00 Strike: $5.27	$0.00	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · derivative · entry 21 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,893 Underlying: Common Stock · 87,374 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	52,766	$0.00 Strike: $7.87	$0.00	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · derivative · entry 20 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,245 Underlying: Common Stock · 52,766 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	90,560	$0.00 Strike: $5.72	$0.00	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · derivative · entry 19 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,485 Underlying: Common Stock · 90,560 shares Expires 2025-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	35,727	$0.00 Strike: $6.14	$0.00	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · derivative · entry 18 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,727 shares Expires 2024-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	51,376	$38.36	$1,970,731.98	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 8 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F5 · price: This sale price represents the weighted average sale price of the shares sold ranging from $37.99 to $38.82 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	72,303	$37.47	$2,708,904.20	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 7 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899,781 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F4 · price: This sale price represents the weighted average sale price of the shares sold ranging from $36.99 to $37.98 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	55,399	$36.41	$2,017,243.79	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 6 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972,084 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $35.99 to $36.98 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	87,349	$35.59	$3,108,401.51	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 5 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,483 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $34.99 to $35.98 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	87,374	$5.27	$460,460.98	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 4 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,114,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	52,766	$7.87	$415,268.42	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 3 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	90,560	$5.72	$518,003.20	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 2 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:34 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	35,727	$6.14	$219,363.78	Disclosure SEC source: 0001299130-21-000105 · certent-form4.xml · nonDerivative · entry 1 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	29,103	$0.00 Strike: $2.63	$0.00	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · derivative · entry 32 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,002 Underlying: Common Stock · 29,103 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over a four year period, provided that the Reporting Person continues to serve through each vesting date. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	86,047	$0.00 Strike: $5.27	$0.00	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · derivative · entry 31 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,267 Underlying: Common Stock · 86,047 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	86,022	$0.00 Strike: $7.87	$0.00	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · derivative · entry 30 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,011 Underlying: Common Stock · 86,022 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	86,065	$0.00 Strike: $5.72	$0.00	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · derivative · entry 29 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,045 Underlying: Common Stock · 86,065 shares Expires 2025-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionStock Option (right to buy) · Derivative	86,084	$0.00 Strike: $6.14	$0.00	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · derivative · entry 28 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,727 Underlying: Common Stock · 86,084 shares Expires 2024-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	72,562	$36.85	$2,673,692.01	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 22 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F13 · price: This sale price represents the weighted average sale price of the shares sold ranging from $36.57 to $37.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	74,119	$35.99	$2,667,691.05	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 21 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,967 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F12 · price: This sale price represents the weighted average sale price of the shares sold ranging from $35.57 to $36.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	113,308	$35.10	$3,977,224.11	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 20 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F11 · price: This sale price represents the weighted average sale price of the shares sold ranging from $34.57 to $35.56 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	42,378	$34.22	$1,450,344.67	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 19 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,108,394 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F10 · price: This sale price represents the weighted average sale price of the shares sold ranging from $33.57 to $34.56 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	18,259	$32.98	$602,090.53	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 18 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150,772 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F9 · price: This sale price represents the weighted average sale price of the shares sold ranging from $32.41 to $33.39 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	28,595	$31.71	$906,633.07	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 17 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,169,031 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F8 · price: This sale price represents the weighted average sale price of the shares sold ranging from $31.38 to $32.34 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	SaleCommon Stock	24,100	$30.90	$744,641.80	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 16 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,197,626 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F7 · price: This sale price represents the weighted average sale price of the shares sold ranging from $30.37 to $31.36 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	29,103	$2.63	$76,540.89	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 15 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,221,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	86,047	$5.27	$453,467.69	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 14 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,192,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	86,022	$7.87	$676,993.14	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 13 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,106,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 23, 2021 Filed Feb 25, 2021 01:50 UTC	PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650	Exercise / conversionCommon Stock	86,065	$5.72	$492,291.80	Disclosure SEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 12 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,020,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.